Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

China · Delayed Price · Currency is CNY

59.35

+0.50 (0.85%)

Apr 29, 2026, 3:00 PM CST

-20.11% (1Y)

Market Cap	24.02B
Revenue (ttm)	3.70B
Net Income (ttm)	1.03B
Shares Out	408.19M
EPS (ttm)	2.52
PE Ratio	23.35
Forward PE	18.82
Dividend	0.62 (1.07%)
Ex-Dividend Date	May 9, 2025

Volume	4,674,906
Average Volume	2,831,549
Open	55.57
Previous Close	58.85
Day's Range	54.54 - 59.88
52-Week Range	55.71 - 93.52
Beta	-0.02
RSI	32.22
Earnings Date	Apr 29, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1996

Employees 3,644

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688278

Full Company Profile

Financial Performance

In 2025, Xiamen Amoytop Biotech's revenue was 3.70 billion, an increase of 31.18% compared to the previous year's 2.82 billion. Earnings were 1.03 billion, an increase of 24.61%.

Financial Statements

News

There is no news available yet.